The Palfabor Group's Bitawibe and Metawe combination therapy has been approved in China.

On June 15, the Pierre Fabre Group announced that the combination therapy of Braftovi and Mektovi has been officially approved by the Chinese National Medical Products Administration for the treatment of adult patients with BRAFV600E mutated metastatic non-small cell lung cancer.